Centre of Genomics and Policy at McGill University, Canada.
J Law Med Ethics. 2011 Winter;39(4):605-13. doi: 10.1111/j.1748-720X.2011.00627.x.
Research now provides participants greater indications of genetic risk for disease, even for conditions incidental to the research study. Given this development, should such information also be disclosed to the family of research participants? There has been some indication at the national level that genetic risk information can be disclosed to participants' families; however, limited attention has been given to returning research results to family. Thus, we have also incorporated the discussion surrounding the disclosure of genetic risk discovered in the clinic (e.g., genetic testing). A number of important questions are examined: Should genetic research results be provided to family? Are there differences between clinical and research findings that would prevent research results from being disclosed to family? Who should make the disclosure, if in fact it is done at all? We conclude by noting that the return of results is increasingly accepted as technology permits the discovery of more and more medically useful data. However, debates of whether results should be returned to participants must first be settled before moving to familial disclosure.
研究现在为参与者提供了更多关于疾病遗传风险的信息,即使是对于研究本身无关的情况也是如此。考虑到这一发展,是否也应该向研究参与者的家属披露这些信息呢?在国家层面上,已经有一些迹象表明可以向参与者的家属披露遗传风险信息;然而,对于将研究结果返还给家属的问题关注有限。因此,我们也纳入了围绕在诊所发现的遗传风险披露的讨论(例如,基因检测)。我们考察了一些重要问题:是否应该向家属提供遗传研究结果?临床和研究结果之间是否存在差异,从而阻止将研究结果披露给家属?如果确实要进行披露,应由谁来进行披露?我们最后指出,随着技术允许发现越来越多具有医学用途的数据,结果的返还越来越被接受。然而,在向家属披露结果之前,必须首先解决是否应该将结果返还给参与者的争论。